Abbott Molecular
Abbott Molecular is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Abbott Molecular?
The 2026-10-09 snapshot links Abbott Molecular to 5 distinct CTIS trials. Recorded services include Laboratory services, IDH1 Assay, MRD Samples. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Abbott Molecular?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Abbott Molecular conducted?
The linked trials record locations in 11 countries, including Germany, France, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Abbott Molecular delivered services.
What can this page tell me about Abbott Molecular's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Abbott Molecular. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Abbott Molecular Inc.